论文部分内容阅读
Objective: To systematically evaluate the effect of Xuesaitong injection combined with edaravone injection on hemorheology indexes in patients with acute cerebral infarction. Methods: Search CNKI, WanFang, VIP, SinoMed, PubMed, Cochrane Library and other databases, collect randomized controlled trials (RCTs) of Xuesaitong combined with edaravone in the treatment of acute cerebral infarction from the establishment of the database to November 2020, using RevMan 5.3 software Perform Meta analysis. Results: 10 RCTs were included, with a total of 834 patients, 417 in the experimental group and 417 in the control group. The results of Meta analysis showed that the experimental group was better than the control group in improving the whole plasma viscosity (MD=-0.73, 95％CI[ -0.83, -0.63], P<0.00001); in terms of improving the thrombosis coefficient, the test group is better than the control group (MD=-0.19, 95％CI[-0.22,-0.15], P<0.00001); In terms of platelet aggregation rate, the test group was better than the control group (MD=-0.21, 95％CI[-0.25,-0.17], P<0.00001). GRADE systematically evaluates whole plasma viscosity, thrombosis coefficient, and platelet aggregation rate, showing that the level of evidence is low or very low, and the strength of the recommendation is weak. Conclusion: Xuesaitong injection combined with edaravone injection has relatively satisfactory results in improving hemorheology indexes in patients with acute cerebral infarction, and there is no obvious safety problem. However, due to the small number of included studies and the total sample size, and the limitation of the quality of the included original studies, the results of this study need to be designed with strict, high-quality, large-sample, multi-center, and more internationally recognized clinical outcome indicators and efficacy experiments to verify, in order to obtain stronger evidence-based medicine.